Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 9/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15268100 | 0.99 | ALDH1A1 (0.48) | ALDH1A1MAPTSMN1; SMN2HPGDLMNA | |
| SCHEMBL4021910 | 0.87 | CHRNA7 (0.43) | APPMAOAMAOB | |
| SCHEMBL10329385 | 0.84 | ACACB (0.45) | ALDH1A1MAPTSMN1; SMN2HPGDLMNA | |
| SCHEMBL11950259 | 0.83 | DRD2 (0.41) | ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL11950262 | 0.83 | DRD2 (0.41) | ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL13351444 | 0.83 | ALDH1A1 (0.49) | ALDH1A1MAPTSMN1; SMN2HPGDLMNA | |
| SCHEMBL12619904 | 0.82 | KDM4E (0.44) | ALDH1A1SMN1; SMN2LMNAKDM4EMAOB | |
| SCHEMBL13578039 | 0.82 | DRD2 (0.42) | ALDH1A1MAPTKDM4E | |
| SCHEMBL12312110 | 0.81 | NR5A1 (0.49) | APP | |
| SCHEMBL8096022 | 0.81 | TP53 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842830-B2 | Transition-metal charge-transport materials, methods of fabrication thereof, and methods of use thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2010-11-30 | — | — | US | disclosed |
| WO-2009092671-A2 | ORGANIC LIGHT EMITTING SYSTEMS | BASF SE (DE) | 2009-07-30 | — | — | WO | disclosed |
| US-20080121870-A1 | Transition-Metal Charge Transport Materials, Methods Of Fabrication Thereof, And Methods Of Use Thereof | GEORGIA TECH RESEACH CORPORATION | 2008-05-29 | — | — | US | disclosed |
| WO-2005123754-A2 | TRANSITION-METAL CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080121870-A1 | Transition-Metal Charge Transport Materials, Methods Of Fabrication Thereof, And Methods Of Use Thereof | SLC39A3, SLC6A6, SLC6A9 | ALDH1A1 2421/4885MAPT 806/4885SMN1; SMN2 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.